Editorial: Drugging p53 for non-cancer diseases

Front Pharmacol. 2022 Nov 30:13:1101742. doi: 10.3389/fphar.2022.1101742. eCollection 2022.

Fan Jiang¹, Chun-Guang Li², Sai-Wang Seto^{2

3

4}

¹ Shandong Key Laboratory of Cardiovascular Proteomics and Department of Geriatric Medicine, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
² NICM Health Research Institute, Western Sydney University, Westmead, NSW, Australia.
³ Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong SAR, China.
⁴ Research Centre for Chinese Medicine Innovation, The Hong Kong Polytechnic University, Hong Kong SAR, China.

No abstract available

Keywords: activator; drug discovery; drug target; inhibitor; ligand; non-cancer disease; p53; small molecule.

Publication types